268 related articles for article (PubMed ID: 19568712)
1. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
Hu XM; Liu F; Zheng CM; Li L; Liu C; Zhang SS; Xiao HY; Yang XH; Wang HZ; Xu YG; Hu NP; Ma R
Chin J Integr Med; 2009 Jun; 15(3):193-7. PubMed ID: 19568712
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia.
Chang H; Salma F; Yi QL; Patterson B; Brien B; Minden MD
Leuk Res; 2004 Jan; 28(1):43-8. PubMed ID: 14630079
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
[TBL] [Abstract][Full Text] [Related]
4. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
6. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Tavernier E; Le QH; Elhamri M; Thomas X
Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
[TBL] [Abstract][Full Text] [Related]
9. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
[TBL] [Abstract][Full Text] [Related]
11. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
Baer MR; George SL; Sanford BL; Mrózek K; Kolitz JE; Moore JO; Stone RM; Powell BL; Caligiuri MA; Bloomfield CD; Larson RA;
Leukemia; 2011 May; 25(5):800-7. PubMed ID: 21321569
[TBL] [Abstract][Full Text] [Related]
12. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Delaunay J; Vey N; Leblanc T; Fenaux P; Rigal-Huguet F; Witz F; Lamy T; Auvrignon A; Blaise D; Pigneux A; Mugneret F; Bastard C; Dastugue N; Van den Akker J; Fière D; Reiffers J; Castaigne S; Leverger G; Harousseau JL; Dombret H; ; ; ; ;
Blood; 2003 Jul; 102(2):462-9. PubMed ID: 12649129
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia.
de Nully Brown P; Jurlander J; Pedersen-Bjergaard J; Victor MA; Geisler CH
Leuk Res; 1997 Oct; 21(10):985-95. PubMed ID: 9403009
[TBL] [Abstract][Full Text] [Related]
19. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
[TBL] [Abstract][Full Text] [Related]
20. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
